Depression

M&A

Eli Lilly to Pay up to $3.8B for AtaiBeckley in Big Pharma’s Latest Psychedelic Foray

Photo via Kris Tripplaar/Sipa USA/Newscom

The deal gives Eli Lilly access to a ⁠psychedelic-based nasal spray that studies show curbs treatment-resistant depression in a single dose.

1 min read

Photo illustration by Connor Lin / The Daily Upside, Photo by Sveipe via iStock

Healthcare

Psychedelic Nation? Psilocybin Treatments Offer New Hope for People Prozac Hasn’t Helped

Psychedelic medications, backed by the White House, may alter the prognosis for people with treatment-resistant depression, but risks remain.

5 min read

Sign Up for The Daily Upside to Unlock This Article

Sharp news & analysis on finance, economics, and investing.